Canagliflozin attenuates thioacetamide-induced liver injury through modulation of HMGB1/RAGE/TLR4 signaling pathways-Reference-Cited by-同舟云学术

Canagliflozin attenuates thioacetamide-induced liver injury through modulation of HMGB1/RAGE/TLR4 signaling pathways

Published:2023-06 Issue: Volume:322 Page:121654
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Abdelmageed Marwa E.^ORCID,Abdelrahman Rehab S.^ORCID

Funder

Mansoura University

Faculty of Veterinary Medicine, Kasetsart University

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference64 articles.

1. Drug metabolism in the liver;Almazroo;Clin. Liver Dis.,2017

2. A review on the structure and function of liver from avicenna point of view and its comparison with conventional Medicine;Azadeh;Trad. Integrat. Med.,2019

3. Burden of liver diseases in the world;Asrani;J. Hepatol.,2019

4. Acute liver failure;Bernal;N. Engl. J. Med.,2013

5. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats;Wallace;Lab. Anim,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-09-10

2. Protective effects of insulin on dry eye syndrome via TLR4/NF-κB pathway: based on network pharmacology and in vitro experiments validation;Frontiers in Pharmacology;2024-08-28

3. Hepatoprotective effect of L-carnitine is achieved via activating Nrf2 and targeting TLR4 signaling pathways in Thioacetamide –induced liver fibrosis in rats;2024-07-24

4. Activation of AMPK/mTOR-Driven Autophagy and Suppression of the HMGB1/TLR4 Pathway with Pentoxifylline Attenuates Doxorubicin-Induced Hepatic Injury in Rats;Pharmaceuticals;2024-05-26

5. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors;Trends in Endocrinology & Metabolism;2024-05